Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations.
Volcy
M
M
The New England Centre for Headache, Stamford, CT 06902-1251, USA.
Tepper
S J
SJ
Rapoport
A M
AM
Sheftell
F D
FD
Bigal
M E
ME
D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D000700:Analgesics / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications; D001241:Aspirin / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications; D003863:Depression / Q000150:complications; D050031:Hashimoto Disease / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D007333:Insulin Resistance; D008297:Male; D008575:Meniere Disease / Q000150:complications; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009777:Occipital Bone; D013705:Temporomandibular Joint Disorders / Q000150:complications; D014277:Trigeminal Neuralgia / Q000150:complications / Q000188:drug therapy*
D000700:Analgesics; D009465:Neuromuscular Agents; D000082:Acetaminophen; D002110:Caffeine; D019274:Botulinum Toxins, Type A; D001241:Aspirin